VG Life Sciences Secures Patent For Cell-Protective IBD Treatment

VG Life Sciences Secures Patent For Cell-Protective IBD Treatment
VG Life Sciences (VGLS), a biotechnology company committed to developing therapies for infectious and autoimmune diseases, recently announced that the U.S. Patent and Trademark Office (USPTO) has issued the company a Patent No. 8906846 covering a new method to treat inflammatory bowel disease (IBD) via administrating a CLIP-inducing agent. This patent, along with the company’s already-established intellectual properties, demonstrates VG Life Science’s continued efforts to advance the potential of

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *